[CAS NO. 722494-26-0]  bpV (HOpic)

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [722494-26-0]

Catalog
SLK-S8651
Brand
Selleck
CAS
722494-26-0

DESCRIPTION [722494-26-0]

Overview

MDLMFCD01862576
Molecular Weight347.24
Molecular FormulaC6H4NO8V.2K
SMILESOC1=CC=C(C(O[V](O[O-])(O[O])=O)=O)N=C1.[K+].[K+]

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM2.8799 mL14.3993 mL28.7985 mL
5 mM0.5760 mL2.8799 mL5.7597 mL
10 mM0.2880 mL1.4399 mL2.8799 mL
50 mM0.0576 mL0.2880 mL0.5760 mL

Description

bpV (HOpic) (Bisperoxovanadium (HOpic)) is a potent inhibitor of with an of 14 nM. The IC50s for PTP-β and PTP-1B are about 350- and 1800-fold higher than the IC50 for PTEN, respectively.

Targets

PTEN [1]
(Cell-free assay)
14 nM

In vitro

1 μM BpV(Hopic) treatment is capable of increasing the in vitro migration of C2C12 myoblasts, without significantly reducing their ability to differentiate and fuse into multinucleated myotubes. The effects on myoblast migration is in conjuction with enhanced AKT and ERK1/2 signaling.

In vivo

Pharmacological inhibition of PTEN with bpV(HOpic) exacerbates renal dysfunction and promotes tubular damage in mice with IRI(renal ischemia/reperfusion injury) compared with vehicle-treated mice with IRI. PTEN inhibition enhances tubular cell apoptosis in kidneys with IRI, which is associated with excessive caspase-3 activation. Furthermore, PTEN inhibition expands the infiltration of neutrophils and macrophages into kidneys with IRI, which is accompanied by increased expression of the proinflammatory molecules.